TY  - JOUR
AU  - Anderluh, Marko
AU  - Berti, Francesco
AU  - Bzducha-Wróbel, Anna
AU  - Chiodo, Fabrizio
AU  - Colombo, Cinzia
AU  - Compostella, Federica
AU  - Durlik, Katarzyna
AU  - Ferhati, Xhenti
AU  - Holmdahl, Rikard
AU  - Jovanović, Dragana J.
AU  - Kaca, Wieslaw
AU  - Lay, Luigi
AU  - Marinović-Cincović, Milena
AU  - Marradi, Marco
AU  - Ozil, Musa
AU  - Polito, Laura
AU  - Reina-Martin, Josè Juan
AU  - Reis, Celso A.
AU  - Sackstein, Robert
AU  - Silipo, Alba
AU  - Švajger, Urban
AU  - Vaněk, Ondřej
AU  - Yamamoto, Fumiichiro
AU  - Richichi, Barbara
AU  - van Vliet, Sandra J.
PY  - 2021
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9815
AB  - Glycan structures are common posttranslational modifications of proteins, which serve multiple important structural roles (for instance in protein folding), but also are crucial participants in cell–cell communications and in the regulation of immune responses. Through the interaction with glycan-binding receptors, glycans are able to affect the activation status of antigen-presenting cells, leading either to induction of pro-inflammatory responses or to suppression of immunity and instigation of immune tolerance. This unique feature of glycans has attracted the interest and spurred collaborations of glyco-chemists and glyco-immunologists to develop glycan-based tools as potential therapeutic approaches in the fight against diseases such as cancer and autoimmune conditions. In this review, we highlight emerging advances in this field, and in particular, we discuss on how glycan-modified conjugates or glycoengineered cells can be employed as targeting devices to direct tumor antigens to lectin receptors on antigen-presenting cells, like dendritic cells. In addition, we address how glycan-based nanoparticles can act as delivery platforms to enhance immune responses. Finally, we discuss some of the latest developments in glycan-based therapies, including chimeric antigen receptor (CAR)-T cells to achieve targeting of tumor-associated glycan-specific epitopes, as well as the use of glycan moieties to suppress ongoing immune responses, especially in the context of autoimmunity.
T2  - The FEBS Journal
T1  - Emerging glyco-based strategies to steer immune responses
VL  - 288
IS  - 16
SP  - 4746
EP  - 4772
DO  - 10.1111/febs.15830
ER  - 

@article{
author = "Anderluh, Marko and Berti, Francesco and Bzducha-Wróbel, Anna and Chiodo, Fabrizio and Colombo, Cinzia and Compostella, Federica and Durlik, Katarzyna and Ferhati, Xhenti and Holmdahl, Rikard and Jovanović, Dragana J. and Kaca, Wieslaw and Lay, Luigi and Marinović-Cincović, Milena and Marradi, Marco and Ozil, Musa and Polito, Laura and Reina-Martin, Josè Juan and Reis, Celso A. and Sackstein, Robert and Silipo, Alba and Švajger, Urban and Vaněk, Ondřej and Yamamoto, Fumiichiro and Richichi, Barbara and van Vliet, Sandra J.",
year = "2021",
abstract = "Glycan structures are common posttranslational modifications of proteins, which serve multiple important structural roles (for instance in protein folding), but also are crucial participants in cell–cell communications and in the regulation of immune responses. Through the interaction with glycan-binding receptors, glycans are able to affect the activation status of antigen-presenting cells, leading either to induction of pro-inflammatory responses or to suppression of immunity and instigation of immune tolerance. This unique feature of glycans has attracted the interest and spurred collaborations of glyco-chemists and glyco-immunologists to develop glycan-based tools as potential therapeutic approaches in the fight against diseases such as cancer and autoimmune conditions. In this review, we highlight emerging advances in this field, and in particular, we discuss on how glycan-modified conjugates or glycoengineered cells can be employed as targeting devices to direct tumor antigens to lectin receptors on antigen-presenting cells, like dendritic cells. In addition, we address how glycan-based nanoparticles can act as delivery platforms to enhance immune responses. Finally, we discuss some of the latest developments in glycan-based therapies, including chimeric antigen receptor (CAR)-T cells to achieve targeting of tumor-associated glycan-specific epitopes, as well as the use of glycan moieties to suppress ongoing immune responses, especially in the context of autoimmunity.",
journal = "The FEBS Journal",
title = "Emerging glyco-based strategies to steer immune responses",
volume = "288",
number = "16",
pages = "4746-4772",
doi = "10.1111/febs.15830"
}

Anderluh, M., Berti, F., Bzducha-Wróbel, A., Chiodo, F., Colombo, C., Compostella, F., Durlik, K., Ferhati, X., Holmdahl, R., Jovanović, D. J., Kaca, W., Lay, L., Marinović-Cincović, M., Marradi, M., Ozil, M., Polito, L., Reina-Martin, J. J., Reis, C. A., Sackstein, R., Silipo, A., Švajger, U., Vaněk, O., Yamamoto, F., Richichi, B.,& van Vliet, S. J.. (2021). Emerging glyco-based strategies to steer immune responses. in The FEBS Journal, 288(16), 4746-4772.
https://doi.org/10.1111/febs.15830

Anderluh M, Berti F, Bzducha-Wróbel A, Chiodo F, Colombo C, Compostella F, Durlik K, Ferhati X, Holmdahl R, Jovanović DJ, Kaca W, Lay L, Marinović-Cincović M, Marradi M, Ozil M, Polito L, Reina-Martin JJ, Reis CA, Sackstein R, Silipo A, Švajger U, Vaněk O, Yamamoto F, Richichi B, van Vliet SJ. Emerging glyco-based strategies to steer immune responses. in The FEBS Journal. 2021;288(16):4746-4772.
doi:10.1111/febs.15830 .

Anderluh, Marko, Berti, Francesco, Bzducha-Wróbel, Anna, Chiodo, Fabrizio, Colombo, Cinzia, Compostella, Federica, Durlik, Katarzyna, Ferhati, Xhenti, Holmdahl, Rikard, Jovanović, Dragana J., Kaca, Wieslaw, Lay, Luigi, Marinović-Cincović, Milena, Marradi, Marco, Ozil, Musa, Polito, Laura, Reina-Martin, Josè Juan, Reis, Celso A., Sackstein, Robert, Silipo, Alba, Švajger, Urban, Vaněk, Ondřej, Yamamoto, Fumiichiro, Richichi, Barbara, van Vliet, Sandra J., "Emerging glyco-based strategies to steer immune responses" in The FEBS Journal, 288, no. 16 (2021):4746-4772,
https://doi.org/10.1111/febs.15830 . .